Apsara Sharma and Mukthinuthalapati Mathrusri Annapurna*

Department of Pharmaceutical Analysis, GITAM School of Pharmacy, GITAM University, Visakhapatnam, India

*Corresponding Author: Mukthinuthalapati Mathrusri Annapurna, Department of Pharmaceutical Analysis, GITAM School of Pharmacy, GITAM University, Visakhapatnam, India.

Received: January 22, 2024; Published: January 31, 2024

Abstract

Tenofovir disproxil fumarate is a nucleotide analog reverse transcriptase inhibitor. Tenofovir is an anti-retroviral drug which acts by blocking the reverse transcriptase enzyme that is necessary for the viral production in HIV-infected people. In the present study the authors have summarised the analytical techniques so far developed for the estimation of Tenofovir disproxil fumarate in pharmaceutical formulations as well as the biological fluids.

Keywords: Tenofovir Disproxil Fumarate; Spectrophotometry; HPLC; HPTLC; LC-MS

References

1. Kearney BP., et al. "Pharmacokinetics and dosing recommendations of tenofovir disoproxil fumarate in hepatic or renal impairment". Clinical Pharmacokinetics11 (2006): 1115-1124.
2. Shela Rani T., et al. "Spectrophotometric method for estimation of Tenofovir disoproxil fumarate in tablet”. Research and Reviews: Journal of Pharmaceutical Analysis 1 (2012): 9-12.
3. Gnanarajan G., et al. "A validated method for development of Tenofovir as API and tablet dosage forms by UV Spectroscopy”. Journal of Young Pharmacists 4 (2009): 351-353.
4. Mohammad Yunoos., et al. "A simple validated uv spectrophotometric method for the estimation of Tenofovir disoproxil fumarate in bulk and pharmaceutical dosage form”. Research Journal of Pharmacy and Technology 4 (2015): 365-368.
5. Shirkhedkar AA., et al. "Application of UV-spectrophotometric methods for estimation of Tenofovir disoproxil fumarate in tablets”. Pakistan Journal of Pharmaceutical Sciences 1 (2009): 27-29.
6. Pratapareddy AJ and Chakravarthi. “New spectrophotometric determination of Tenofovir disoproxil fumaratein bulk and pharmaceutical dosage form”. IOSR Journal of Applied Chemistry2 (2012): 29-33.
7. Rajan VR and Prathamesh PT. “UV spectrophotometric estimation of Tenofovir disoproxil fumarate by area under curve methods in bulk and pharmaceutical dosage form”. Asian Journal of Research in Chemistry 1 (2020): 7-11.
8. Debaje Priyanka D., et al. "Force degradation study of Tenofovir disoproxil fumarate by UV spectrophotometric method”. Asian Journal of Pharmaceutical Research and Development2 (2020): 21-25.
9. Nilesh M Nikam and Dhanashri Pagare R. “Force degradation study of tenofovir disoproxil fumarate by uv-spectrophotometric method”. Pharmaceutical Resonance2 (2021): 110-113.
10. Susmitha K., et al. "Extractive spectrophotometric determination of Tenofovir disoproxil fumarate using acidic triphenylmethane dyes”. ISRN Spectroscopy (2014).
11. Manojkumar D., et al. "A new RP-HPLC method for the determination of Tenofovir disoproxil fumarate in pure form and pharmaceutical formulation”. International Journal of Research in Pharmaceutical Sciences 1 (2020): 17-24.
12. Zhenzhen Zhang., et al. "Development of a validated HPLC method for the determination of Tenofovir disoproxil fumarate using a green enrichment process”. Annals Methods 7 (2015): 6290-6298.
13. 13.   Rinchi Bora. “Analytical method development, validation, synthesis, characterization and forced degradation study of Tenofovir disoproxil fumarate and its impurities”. Xi'an Shiyou Daxue Xuebao (Ziran Kexue Ban)”. Journal of Xi'an Shiyou University 17.7 (2021): 179-186.
14. Dhanalakshmi K., et al. "RP-HPLC method validation for estimation of Tenofovir disoproxil fumarate in pharmaceutical oral dosage form”. Research Journal of Pharmacy and Technology 2 (2023): 777-780.
15. Shweta Havele and Sunil R Dhaneshwar. “Development and validation of a stability-indicating LC method for the determination of Tenofovir disoproxil fumarate in pharmaceutical formulation”. The Scientific World Journal6 (2012): 615-622.
16. Kandagal PB., et al. "RP-HPLC method for the determination of tenofovir in pharmaceutical formulations and spiked human plasma”. Analytical Letters4 (2008: 561-570.
17. Mardia RB., et al. "Development and validation of HPTLC method for estimation of Tenofovir disoproxil fumarate in tablet dosage form”. Journal of Pharmaceutical Science and Bioscientific Research 2 (2012): 73-76.
18. Shweta H and Sunil RD. “Stress studies of Tenofovir disoproxil fumarate by HPTLC in bulk drug and pharmaceutical formulation”. Scientific World Journal 2012 (2012): 894136.
19. Li Lin., et al. "Study on Quality Control of Tenofovir Disoproxil Fumarate Enantiomers by High-Performance Liquid Chromatography–Mass Spectrometry”. Chromatographia 86 (2023): 213-222.
20. Choi SO., et al. "Development of an LC–MS Method for Measuring TNF in Human Vaginal Tissue”. Journal of Chromatographic Science 48 (2010).

Citation

Citation: Apsara Sharma and Mukthinuthalapati Mathrusri Annapurna. “Analytical Methods for the Quantification of Tenofovir - A Review".Acta Scientific Pharmaceutical Sciences 8.2 (2024): 71-73.

Copyright

Copyright: © 2024 Apsara Sharma and Mukthinuthalapati Mathrusri Annapurna. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.